Table 1.

Clinical features and volumetric quantifications of the study patients

PatientAge (yr)GenderNeurological diseaseMedicationTIV (mm3)Normalized MLV volumeNormalized venous volume
64 IIH + CSF leak  1,414,960 3,770.45 19,190.93 
73 IIH + CSF leak  1,397,400 3,429.09 13,044.44 
49 IIH Acetazolamide 1,158,840 2,474.28 10,802.18 
40 IIH Acetazolamide 1,273,760 2,579.78 13,746.00 
25 IIH Acetazolamide 1,270,220 2,479.75 14,631.01 
42 JS  1,432,380 7,500.31 10,156.52 
27 MS with acute demyelinating event Tecfidera 480 mg; methylprednisolone (3 g) <10 d 1,546,820 7,372.09 13,081.61 
38 MS with acute demyelinating event Methylprednisolone (3 g) <10 d 1,094,560 2,786.73 10,692.70 
54 MS  1,312,850 3,142.83 16,197.20 
10 67 MS Dimethyl fumarate (14 mg) 1,464,580 7,703.16 22,947.60 
11 37 GSD  1,382,580 15,470.42 20,718.80 
Mean (SEM) 47 (4.82) 4:7 (M:F)   1,340,814 (40,519.6) 5,337.17 (1,200.30) 15,019.00 (1,292.32) 
PatientAge (yr)GenderNeurological diseaseMedicationTIV (mm3)Normalized MLV volumeNormalized venous volume
64 IIH + CSF leak  1,414,960 3,770.45 19,190.93 
73 IIH + CSF leak  1,397,400 3,429.09 13,044.44 
49 IIH Acetazolamide 1,158,840 2,474.28 10,802.18 
40 IIH Acetazolamide 1,273,760 2,579.78 13,746.00 
25 IIH Acetazolamide 1,270,220 2,479.75 14,631.01 
42 JS  1,432,380 7,500.31 10,156.52 
27 MS with acute demyelinating event Tecfidera 480 mg; methylprednisolone (3 g) <10 d 1,546,820 7,372.09 13,081.61 
38 MS with acute demyelinating event Methylprednisolone (3 g) <10 d 1,094,560 2,786.73 10,692.70 
54 MS  1,312,850 3,142.83 16,197.20 
10 67 MS Dimethyl fumarate (14 mg) 1,464,580 7,703.16 22,947.60 
11 37 GSD  1,382,580 15,470.42 20,718.80 
Mean (SEM) 47 (4.82) 4:7 (M:F)   1,340,814 (40,519.6) 5,337.17 (1,200.30) 15,019.00 (1,292.32) 

F, female; M, male. The volumes of MLVs and venous sinuses were normalized against the TIV.

or Create an Account

Close Modal
Close Modal